CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus

Abroad (travel likely)RecruitingPHASE1

Conditions

Refractory Systemic Lupus Erythematosus

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam
Contact: Study coordinator (Liem T Nguyen, PhD) · liem.nt@vinuni.edu.vn · +84 986 565 015

Study leads

Liem T Nguyen, PhD
Principal Investigator
Vinmec Research Institute of Stem Cell and Gene Technology, VinUniversity

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus · Lupus Nephritis (LN) · Sjogren's Syndrome

Abroad (travel likely)RecruitingPHASE1

Bengbu, China

Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE

Systemic Lupus Erythematosus

Abroad (travel likely)RecruitingPHASE1

Nanjing, China

UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis

Systemic Lupus Erythematosus · Lupus Nephritis

Abroad (travel likely)RecruitingPHASE1

Nanjing, China

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Relapsed/Refractory Systemic Lupus Erythematosus · Relapsed/Refractory Systemic Sclerosis · Relapsed/Refractory Idiopathic Inflammatory Myopathies

Abroad (travel likely)RecruitingPHASE1

Beijing, China